3 unknown. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
| Phase 3 | 1 | Unknown 1 |
Follow Stuttering: new trials by email Literature Review of Stuttering trials Research Report on Stuttering
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). Ecopipam 50mg, Ecopipam 100mg - Stuttering, Adult, Childhood-onset Fluency Disorder | Phase 2 / Phase 3 | Unknown | Gerald Maguire, MD | 10 | 2016-09-01 | 2016-10-26 |
| Follow-up of Children After Stuttering Treatment SMS (Short Message Service) reminders - Stuttering | Phase 2 | Unknown | University of Sydney | 180 | 2009-02-01 | 2010-04-26 |
| Spacing Lidcombe Program Clinic Visits The Lidcombe Program for early stuttering - Stuttering | Phase 2 | Unknown | University of Sydney | 120 | 2008-01-01 | 2008-05-20 |
Childhood-Onset Fluency Disorder (1) · Communication Disorders (1) · Language Disorders (1) · Recurrence (1) · Speech Disorders (1)
Nervous System Diseases (3) · Neurobehavioral Manifestations (3) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Communication Disorders (2) · Language Disorders (2) · Speech Disorders (2) · Disease Attributes (1) · Mental Disorders (1) · Neurodevelopmental Disorders (1) · Pathologic Processes (1)
Spermine Synthase (1) · ecopipam (1)
University of Sydney (2) · Gerald Maguire, MD (1)
Australia (2) · Canada (1) · United States (1)
Mark Onslow (1) · Mark Onslow, PhD (1)
PMID 10917410, PMID 12849360, PMID 15026214, PMID 15212606, PMID 15328899, PMID 20075648, PMID 24434529